NCT01710371View on ClinicalTrials.gov

Quantitative 18F-AV-133 PET Imaging in Subjects With Diabetes and Healthy Controls

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Type 2 Diabetes
Interventions
DRUG

18F-AV-133

296 MBq (8 mCi)

DRUG

10% Arginine Hydrochloride-R-Gene 10

Trial Locations (1)

06511

Research Site, New Haven

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Avid Radiopharmaceuticals

INDUSTRY